to screen the chemosensitivity of pancreatic adenocarcinoma cells[2]
as a chemical to study its ability to reverse multidrug resistance (MDR), due to ATP binding cassette (ABC) transporters[3]
生化/生理作用
Active metabolite of irinotecan. Inhibitor of topoisomerase I.
Active metabolite of irinotecan. Inhibitor of topoisomerase I.. Gene expression analysis of colon cancer cell lines treated with SN-38 showed differential effects: the majority of affected genes were down-regulated (including, most strongly, genes related to receptor and kinase activity, signal transduction, apoptosis, RNA processing, protein metabolism and transport, cell cycle and transcription. Some of the up-regulated genes were involved in apoptosis, transcription, development and differentiation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(35), 4438-4444 (2013-11-06)
This phase III study compared treatment with weekly paclitaxel and biweekly irinotecan in patients with advanced gastric cancer refractory to treatment with fluoropyrimidine plus platinum. Patients were randomly assigned to receive either paclitaxel (80 mg/m(2) on days 1, 8, and
Transcripts of the UGT1A gene, encoding half of human UDP-glucuronosyltransferase (UGT) enzymes, undergo alternative splicing, resulting in active enzymes named isoforms 1 (i1s) and novel truncated isoforms 2 (i2s). Here, we investigated the effects of depleting endogenous i2 on drug
Enterovirus 71 (EV71) is one of the causative agents of hand, foot and mouth disease (HFMD) associated with severe neurological disease. EV71's pathogenesis remains poorly understood and the lack of approved antiviral has led to its emergence as a clinically
European journal of cancer (Oxford, England : 1990), 50(2), 320-331 (2013-10-22)
The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen. In the
Clinical and experimental immunology, 172(3), 490-499 (2013-04-23)
Recent studies indicate that chemotherapeutic agents may increase the anti-tumoral immune response. Based on the pivotal role of dendritic cells (DCs) in host tumour-specific immune responses, we investigated the effect of commonly used chemotherapeutic drugs dexamethasone, doxorubicin, cisplatin and irinotecan
Graphene oxide, a monomolecular layer of graphite with oxygen functionalities, holds unique properties valuable for various applications in materials science.
